News
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).
The fourth-quarter 2022 earnings presentation and
Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Valbiotis gibt positive Ergebnisse der klinischen Studie zur Bioverfügbarkeit und Wirkungsweise von TOTUM•854 gegen Bluthochdruck bekannt
Pflichtmitteilung:
Valbiotis (FR0013254851 - ALVAL, PEA / KMU-qualifiziert) (Paris:ALVAL), ein kommerziell ausgerichtetes Forschungs- und Entwicklungsunternehmen, das sich auf wissenschaftliche
Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Against High Blood Pressure
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, with a commercial purpose, committed to scientific
Charles River Laboratories Acquires SAMDI Tech
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired SAMDI Tech, Inc, a leading provider of high-quality, label-free high-throughput screening (HTS)
Aurinia Announces PTAB Has Terminated Inter Partes Review
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States’ Patent and Trademark Office has terminated the Inter Partes
Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces the conversion of the safeguard
Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On January 17
EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss
EQS-News: BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
Novocure Announces Organizational Changes to Prepare for Future Growth
Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17.
Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new
Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of EZ2 Connect MDx for use in diagnostic laboratories, making the IVD platform for automated sample processing
QIAGEN bringt EZ2-Connect-MDx-Plattform für automatisierte Probenverarbeitung in Diagnoselaboren auf den Markt
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Markteinführung von EZ2 Connect MDx für den Einsatz in Diagnoselaboren bekannt gegeben. Damit steht die IVD-Plattform für die
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries
Pfizer Inc. (NYSE: PFE) today announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022.
Press release date / time: Tuesday, February 7, shortly
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of their new CliniPrimeTM suite of Good Manufacturing Practice (GMP)-compliant cellular starting materials
ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported that the
EQS-News: BRAIN Biotech AG reports record figures in fiscal year 2021/22 − despite challenging geopolitical environment
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through